Emtritaf 200/25 200 /25 mg FC tablets
PDF Leaflet Revision Date: 05 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 in adults and adolescents (u226512 years, u226535 kg).
Dosage (summary)
200/25 mg once daily with or without food.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy unless no alternatives; avoid breastfeeding.
Key Drug Interactions
- Anticonvulsants (e.g., carbamazepine, phenytoin)
- Antimycobacterials (e.g., rifampicin)
- St. John's wort
Contraindications
- Hypersensitivity to active substances or excipients
Common side effects
- Diarrhoea
- Nausea
- Headache
Counselling Points
- Take once daily, do not chew or crush tablets.
- Monitor for signs of liver dysfunction.
- Use effective contraception.
Serious warnings
- Lactic acidosis
- Severe hepatomegaly
- Risk of hepatitis B exacerbation upon discontinuation
Important Disclaimer
The Emtritaf 200/25 200 /25 mg FC tablets professional information leaflet below is the property of Macleods Pharmaceuticals Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
